🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. BCMA/CD3 bispecific antibody (CM336)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solitary Bone Plasmacytoma

    phase 2 small molecule active

    1 trial

  2. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  3. BMSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  4. Baricitinib 2 MG [Olumiant]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  5. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Penile Cancer

    phase 2 small molecule active

    1 trial

  6. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  7. Bedaquiline (B)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis, Pulmonary

    phase 2 small molecule active

    1 trial

  8. Befotertinib combined Bevacizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    EGFR

    phase 2 small molecule active

    1 trial

  9. Benmelstobart

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Bicalutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  11. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  12. Bleomycin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphatic Malformation

    phase 2 small molecule active

    1 trial

  13. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 small molecule active

    1 trial

  14. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  15. Bosentan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  16. Bozitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  17. Bronchial basal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease

    phase 2 mab completed

    1 trial

  18. Bronchial basal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchiectasis

    phase 2 mab active

    1 trial

  19. Bu-Yang-Huan-Wu Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    phase 2 small molecule active

    1 trial

  20. C-CAR088

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    2 trials

  21. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  22. CD19X CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-Cell Lymphoma (LBCL)

    phase 2 small molecule active

    1 trial

  23. CD22/CD19 CAR T and auto-HSCT "sandwich" strategy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Acute Lymphoblastic Leukemia

    phase 2 other active

    1 trial

  24. CD25 antibody combined glucocorticoid as first-line treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources